Oslo, Norway, 17 February 2026 – Oncoinvent, a biotech developing a receptor-independent alpha radiopharmaceutical to ...

"The prognosis was so poor that the hospital called in grief counselors to speak with my family and help prepare them." View Entire Post › ...

FDA approved a PD-L1 companion test to identify patients with ovarian, fallopian tube or primary peritoneal cancer who may receive first-line Keytruda. The U.S. Food and Drug Administration (FDA) has ...

Age is the primary risk factor for ovarian cancer.

Stage 1 mesothelioma is localized. The cancer is confined to one side of the chest lining or one area of the abdomen and has ...

Dr Ashish Bangar, Consultant Surgical Oncologist based in Pune, has been nominated in Outlook Magazine's "Best Doctors of ...

But now, 13 years after the FDA initially blessed it for skin cancer, the U.S. regulator has approved Keytruda as a second- ...

The FDA approved pembrolizumab (Keytruda) plus paclitaxel for recurrent ovarian cancers that express PD-L1, the agency ...

The Cancer Action Plan of Washington, or CAPOW, a five-year strategic plan to reduce cancer rates — and cancer deaths — in Washington state just dropped. What action is Fred Hutch taking to drop ...

Chairman and CEO Dr. Amit Kumar said the company views 2026 as a “pivotal year” as it advances two clinical-stage programs: a ...

The approvals stem from the Phase III KEYNOTE-B96 trial data, which was presented at the 2025 ESMO Congress.